Panagiotis Mavros

3.9k total citations · 1 hit paper
59 papers, 2.9k citations indexed

About

Panagiotis Mavros is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Economics and Econometrics. According to data from OpenAlex, Panagiotis Mavros has authored 59 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Pharmacology and 12 papers in Economics and Econometrics. Recurrent topics in Panagiotis Mavros's work include Diabetes Treatment and Management (13 papers), Diabetes Management and Research (11 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). Panagiotis Mavros is often cited by papers focused on Diabetes Treatment and Management (13 papers), Diabetes Management and Research (11 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). Panagiotis Mavros collaborates with scholars based in United States, United Kingdom and Canada. Panagiotis Mavros's co-authors include William C. Gerth, Sheldon X. Kong, Hans‐Georg Eichler, Bengt Jönsson, Robert Deuson, Mogens Hansen, Jørn Herrstedt, Brigitte Bloechl‐Daum, Ronald G. Ehrenberg and D. Yin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and American Journal of Epidemiology.

In The Last Decade

Panagiotis Mavros

59 papers receiving 2.8k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?

2004 623 citations Hans‐Georg Eichler, Sheldon X. Kong et al. Value in Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Panagiotis Mavros United States	22	994	612	518	516	259	59	2.9k
Zanfina Ademi Australia	25	810 0.8×	389 0.6×	379 0.7×	814 1.6×	155 0.6×	201	3.1k
Yana Vinogradova United Kingdom	26	797 0.8×	838 1.4×	215 0.4×	445 0.9×	248 1.0×	67	4.0k
Gérard de Pouvourville France	28	798 0.8×	428 0.7×	345 0.7×	964 1.9×	319 1.2×	177	3.1k
Fiona Taylor United Kingdom	27	1.5k 1.5×	407 0.7×	274 0.5×	778 1.5×	697 2.7×	106	5.0k
Richard H. Chapman United States	32	528 0.5×	488 0.8×	313 0.6×	1.3k 2.6×	397 1.5×	69	3.9k
Jason Oke United Kingdom	23	470 0.5×	580 0.9×	451 0.9×	231 0.4×	347 1.3×	94	4.2k
Zachary J. Ward United States	29	726 0.7×	372 0.6×	651 1.3×	248 0.5×	423 1.6×	74	4.4k
David Wonderling United Kingdom	25	753 0.8×	191 0.3×	186 0.4×	724 1.4×	359 1.4×	47	3.1k
Diana Brixner United States	29	326 0.3×	329 0.5×	205 0.4×	497 1.0×	247 1.0×	174	2.7k
Onur Başer United States	34	847 0.9×	536 0.9×	139 0.3×	633 1.2×	600 2.3×	193	4.1k

Countries citing papers authored by Panagiotis Mavros

Since Specialization

Citations

This map shows the geographic impact of Panagiotis Mavros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Panagiotis Mavros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Panagiotis Mavros more than expected).

Fields of papers citing papers by Panagiotis Mavros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Panagiotis Mavros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Panagiotis Mavros. The network helps show where Panagiotis Mavros may publish in the future.

Co-authorship network of co-authors of Panagiotis Mavros

This figure shows the co-authorship network connecting the top 25 collaborators of Panagiotis Mavros. A scholar is included among the top collaborators of Panagiotis Mavros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Panagiotis Mavros. Panagiotis Mavros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Young, Jessica C., Michael Webster‐Clark, Elizabeth M. Garry, et al.. (2024). Clarifying the causal contrast: An empirical example applying the prevalent new user study design. Pharmacoepidemiology and Drug Safety. 33(4). e5790–e5790. 1 indexed citations

Basu, Anirban, et al.. (2023). Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia. Journal of Managed Care & Specialty Pharmacy. 29(3). 293–302. 1 indexed citations

Correll, Christoph U., Carmela Benson, Bruno Émond, et al.. (2023). Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia. 9(1). 9–9. 11 indexed citations

Webster‐Clark, Michael, Panagiotis Mavros, Elizabeth M. Garry, et al.. (2022). Alternative analytic and matching approaches for the prevalent new‐user design: A simulation study. Pharmacoepidemiology and Drug Safety. 31(7). 796–803. 2 indexed citations

Jakubowiak, Andrzej, Shaji Kumar, Huiling Pei, et al.. (2022). Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. The Oncologist. 27(7). e589–e596. 12 indexed citations

Bash, Lori D., Kellee White, Mehul D. Patel, et al.. (2019). Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database. Cardiology and Therapy. 8(2). 329–343. 4 indexed citations

Desai, Rishi, Mufaddal Mahesri, Julie Barberio, et al.. (2018). Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures. JAMA Network Open. 1(3). e180826–e180826. 59 indexed citations

Patel, Mehul D., et al.. (2017). Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database. Journal of Managed Care & Specialty Pharmacy. 23(6). 684–690. 2 indexed citations

Iglay, Kristy, Xiting Cao, Panagiotis Mavros, et al.. (2015). Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy. Clinical Therapeutics. 37(8). 1813–1821.e1. 38 indexed citations

10.

Iglay, Kristy, et al.. (2014). Systematic Literature Review and Meta-Analysis of Medication Adherence with Once Weekly Versus Once Daily Therapy in Patients with Osteoporosis. Value in Health. 17(3). A8–A8. 2 indexed citations

11.

Black, Christopher M., Ceri Phillips, Paul M. Peloso, et al.. (2013). A European Assessment Of The Impact Of Inadequate Pain Relief (Ipr) On Health-Related Quality Of Life (Qol) In Patients With Knee Osteoarthritis (Oa) In The Survey Of Real World Therapies (Sort). Value in Health. 16(3). A228–A228. 3 indexed citations

12.

Sinclair, Alan J., et al.. (2012). Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes. BMC Endocrine Disorders. 12(1). 1–1. 25 indexed citations

13.

Arden, N K, Brett Hauber, F. Reed Johnson, et al.. (2012). How Do Physicians Weigh Benefits and Risks Associated with Treatments in Patients with Osteoarthritis in the United Kingdom?. The Journal of Rheumatology. 39(5). 1056–1063. 22 indexed citations

14.

Hauber, Brett, N K Arden, Ateesha F. Mohamed, et al.. (2012). A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis. Osteoarthritis and Cartilage. 21(2). 289–297. 75 indexed citations

15.

Guisasola, Fernando Álvarez, Donald Yin, G Nocea, Ying Qiu, & Panagiotis Mavros. (2010). Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. Health and Quality of Life Outcomes. 8(1). 86–86. 66 indexed citations

16.

Zhang, Qiaoyi, Panagiotis Mavros, Samuel S. Engel, et al.. (2010). Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database. Advances in Therapy. 27(4). 223–232. 8 indexed citations

17.

Suh, Dong‐Churl, et al.. (2007). Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK. Lara D. Veeken. 47(4). 458–463. 7 indexed citations

18.

Eichler, Hans‐Georg, Panagiotis Mavros, Olga Geling, Elke Hunsche, & Sijia Kong. (2005). Association between health-related quality of life and clinical efficacy endpoints in rheumatoid arthritis patients after four weeks treatment with anti-inflammatory agents. International Journal of Clinical Pharmacology and Therapeutics. 43(5). 209–216. 11 indexed citations

19.

Langman, M. J. S., et al.. (2004). Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and nonselective NSAIDs. International Journal of Clinical Pharmacology and Therapeutics. 42(5). 260–266. 1 indexed citations

20.

Eichler, Hans‐Georg, Sheldon X. Kong, William C. Gerth, Panagiotis Mavros, & Bengt Jönsson. (2004). Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?. Value in Health. 7(5). 518–528. 623 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact